Products
TWYNEO is a topical treatment for acne1
About Twyneo
TWYNEO is the first and only FDA-approved fixed-dose combination of tretinoin and benzoyl peroxide (BPO) for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older.1,2
For more information about TWYNEO, please visit the US product website.
Partners
TWYNEO is currently available in the US
TWYNEO will be available in Canada in early 2024
Important Safety Information (US)
Indication: TWYNEO® (tretinoin and benzoyl peroxide) Cream, 0.1%/3% is indicated for the topical treatment of acne vulgaris in adults and pediatric patients 9 years of age and older. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in patients treated with TWYNEO Cream were pain (stinging, burning, or pain), dryness, exfoliation, erythema (redness), dermatitis, pruritus (itching) and irritation – all at the application site. Warnings/Precautions: Patients using TWYNEO Cream may experience hypersensitivity reactions, including anaphylaxis (acute allergic reaction), angioedema (rapid swelling), and urticaria (hives). If serious hypersensitivity reaction occurs, discontinue use of TWYNEO Cream immediately and seek medical attention. Skin irritation may be experienced, including application site dryness, pain (stinging, burning or pain), exfoliation, erythema (redness), dermatitis, pruritus (itching) and irritation. Depending upon the severity, use a moisturizer, reduce the frequency of the application, or discontinue use. Avoid application to cuts, abrasions, eczematous, or sunburned skin. TWYNEO Cream may increase photosensitivity, sensitivity to ultraviolet light. Minimize or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment). Use sunscreen or protective clothing when sun exposure cannot be avoided. Discontinue use of TWYNEO Cream at the first evidence of sunburn.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088
EPSOLAY is a topical treatment for rosacea2
About EPSOLAY
EPSOLAY is the first and only FDA-approved BPO topical cream for the treatment of inflammatory lesions of rosacea in adults.3,4
For more information about EPSOLAY, please visit the US product website.
Partners
EPSOLAY is currently available in the US
EPSOLAY will be available in Canada in early 2024
Important Safety Information (US)
Indication: EPSOLAY® (benzoyl peroxide) Cream, 5% is indicated for the treatment of inflammatory lesions of rosacea in adults. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in patients treated with EPSOLAY Cream were pain, erythema (redness), pruritus (itching) and edema (swelling), all at the application site. Warnings/Precautions: Patients using EPSOLAY Cream may experience hypersensitivity reactions, including anaphylaxis (acute allergic reaction), angioedema (rapid swelling), and urticaria (hives). If serious hypersensitivity reaction occurs, discontinue use of EPSOLAY Cream immediately and seek medical attention/initiate appropriate therapy. Skin Irritation/contact dermatitis may be experienced, including erythema (redness), scaling, dryness, and stinging/burning. Irritation and contact dermatitis may occur. Use a moisturizer and discontinue EPSOLAY Cream if symptoms do not improve. Avoid application to cuts, abrasions, eczematous, or sunburned skin. EPSOLAY Cream may increase photosensitivity, sensitivity to ultraviolet light. Minimize or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment). Use sunscreen or protective clothing when sun exposure cannot be avoided. Discontinue use of EPSOLAY Cream at the first evidence of sunburn.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088
References:
- TWYNEO®. Prescribing Information. Galderma Laboratories; 2022.
- Sol-Gel Technologies announces FDA approval of TWYNEO®. Sol-gel.com. July 27, 2021. Accessed August 22, 2023. https://ir.sol-gel.com/news-releases/news-release-details/sol-gel-technologies-announces-fda-approval-twyneor.
- EPSOLAY®. Prescribing Information. Galderma Laboratories; 2023.
- The first-ever encapsulated benzoyl peroxide for rosacea is now available. Rosacea.org. June 7, 2022. Accessed August 22, 2023. https://www.rosacea.org/blog/2022/june/epsolay-first-ever-encapsulated-benzoyl-peroxide-for-rosacea-now-available.